We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
Read MoreHide Full Article
Key Takeaways
GEHC posted Q2 adjusted EPS of $1.06, beating estimates by 16.5% and rising 6% year over year.
Quarterly revenues rose 3% to $5B, driven by U.S. market strength in Imaging and Pharma Diagnostics.
GEHC raised its 2025 EPS forecast to $4.43-$4.63 and expects 3% organic revenue growth for the year.
GE HealthCare (GEHC - Free Report) reported second-quarter 2025adjusted earnings per share (EPS) of $1.06, which beat the Zacks Consensus Estimate of 91 cents by 16.5%. Also, the bottom line improved 6% year over year.
GAAP EPS in the quarter was also $1.06, up 13.9% from the year-ago level.
Revenue Details
The company reported revenues of $5 billion, up 3% year over year on a reported basis and 2% organically. The top line beat the Zacks Consensus Estimate by 0.1%. Total company orders increased 3% organically year over year.
Revenues were driven by strength in the U.S. market across all segments, especially in the Imaging and Pharmaceutical Diagnostics segments.
Segmental Details
Imaging
Revenues from this segment totaled $2.2 billion, up 2% year over year on a reported basis and 1% organically.
Segment EBIT was $188 million, down 10% year over year.
Advanced Visualization Solutions
Revenues totaled $1.29 billion, up 3% year over year on a reported basis and 2% on an organic basis.
Segment EBIT was $267 million, up 4% year over year.
Patient Care Solutions
Revenues amounted to $778 million, up 1% year over year on a reported basis and flat organically.
Segment EBIT was $60 million, down 23% year over year.
Pharmaceutical Diagnostics
Revenues totaled $729 million, up 14% year over year and 5% on an organic basis.
Segment EBIT was $213 million, up 7% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
Net income margin was 9.7%, up 80 basis points from the prior-year level, primarily attributable to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the second quarter was $344 million compared with $300 million a year ago.
Financial Position
GEHC exited the second quarter with cash, cash equivalents and investments of $3.76 billion compared with $2.47 billion in the previous quarter.
Total assets increased to $35.5 billion from $33.59 billion on a sequential basis.
2025 Guidance
GE HealthCare raised its earnings and organic revenue guidance for 2025.
The company now expects adjusted EPS in the range of $4.43-$4.63, up from $3.90-$4.10 expected previously. The guide includes approximately 45 cents of unfavorable impact of tariffs. Revenues are now anticipated to grow 3% organically, up from 2-3% expected previously and therefore reflecting continued demand for its products and services. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.02 and $20.31 billion, respectively.
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
Key Takeaways
GE HealthCare (GEHC - Free Report) reported second-quarter 2025adjusted earnings per share (EPS) of $1.06, which beat the Zacks Consensus Estimate of 91 cents by 16.5%. Also, the bottom line improved 6% year over year.
GAAP EPS in the quarter was also $1.06, up 13.9% from the year-ago level.
Revenue Details
The company reported revenues of $5 billion, up 3% year over year on a reported basis and 2% organically. The top line beat the Zacks Consensus Estimate by 0.1%. Total company orders increased 3% organically year over year.
Revenues were driven by strength in the U.S. market across all segments, especially in the Imaging and Pharmaceutical Diagnostics segments.
Segmental Details
Imaging
Revenues from this segment totaled $2.2 billion, up 2% year over year on a reported basis and 1% organically.
Segment EBIT was $188 million, down 10% year over year.
Advanced Visualization Solutions
Revenues totaled $1.29 billion, up 3% year over year on a reported basis and 2% on an organic basis.
Segment EBIT was $267 million, up 4% year over year.
Patient Care Solutions
Revenues amounted to $778 million, up 1% year over year on a reported basis and flat organically.
Segment EBIT was $60 million, down 23% year over year.
Pharmaceutical Diagnostics
Revenues totaled $729 million, up 14% year over year and 5% on an organic basis.
Segment EBIT was $213 million, up 7% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Margins
Net income margin was 9.7%, up 80 basis points from the prior-year level, primarily attributable to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the second quarter was $344 million compared with $300 million a year ago.
Financial Position
GEHC exited the second quarter with cash, cash equivalents and investments of $3.76 billion compared with $2.47 billion in the previous quarter.
Total assets increased to $35.5 billion from $33.59 billion on a sequential basis.
2025 Guidance
GE HealthCare raised its earnings and organic revenue guidance for 2025.
The company now expects adjusted EPS in the range of $4.43-$4.63, up from $3.90-$4.10 expected previously. The guide includes approximately 45 cents of unfavorable impact of tariffs. Revenues are now anticipated to grow 3% organically, up from 2-3% expected previously and therefore reflecting continued demand for its products and services. The Zacks Consensus Estimate for 2025 EPS and revenues is pegged at $4.02 and $20.31 billion, respectively.
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.